Longitudinal and proteome-wide analyses of antibodies in COVID-19 patients reveal features of the humoral immune response to SARS-CoV-2.

Abstract

Introduction:

The SARS-CoV-2 pandemic has endangered global health, the world economy, and societal values. Despite intensive measures taken around the world, morbidity and mortality remain high as many countries face new waves of infection and the spread of new variants. Worryingly, more and more variants are now being identified, such as 501Y.V1 (B.1.1.7) in the UK, 501Y.V2 (B.1.351) in South Africa, 501Y.V3 in Manaus, Brazil, and B.1.617/B.1.618 in India, which could lead to a severe epidemic rebound. Moreover, some variants have a stronger immune escape ability. To control the new SARS-CoV-2 variant, we may need to develop and redesign new vaccines repeatedly. So it is important to investigate how our immune system combats and responds to SARS-CoV-2 infection to develop safe and effective medical interventions.

Objectives:

In this study, we performed a longitudinal and proteome-wide analysis of antibodies in the COVID-19 patients to revealed some immune processes of COVID-19 patients against SARS-CoV-2 and found some dominant epitopes of a potential vaccine.

Methods:

Microarray assay, Antibody depletion assays, Neutralization assay.

Results:

We profiled a B-cell linear epitope landscape of SARS-CoV-2 and identified the epitopes specifically recognized by either IgM, IgG, or IgA. We found that epitopes more frequently recognized by IgM are enriched in non-structural proteins. We further identified epitopes with different immune responses in severe and mild patients. Moreover, we identified 12 dominant epitopes eliciting antibodies in most COVID-19 patients and identified five key amino acids of epitopes. Furthermore, we found epitope S-82 and S-15 are perfect immunogenic peptides and should be considered in vaccine design.

Conclusion:

This data provide useful information and rich resources for improving our understanding of viral infection and developing a novel vaccine/neutralizing antibodies for the treatment of SARS-CoV-2.

• Authors: Jianxin Wang, Yongfei Yang, Te Liang, Ning Yang, Tao Li, Chang Zheng, Nianzhi Ning, Deyan Luo, Xiaolan Yang, Zhili He, Guang Yang, Bo Li, Jie Gao, Wenjing Yu, Saisai Gong, Yanyu Huang, Jiajia Li, Hongye Wang, Hao Zhang, Tian Zhang, Peiran Li, Yongli Li, Jiayu Dai, Xiaomei Zhang, Boan Li, Xiaobo Yu, Hui Wang
• Journal: Journal of advanced research (J Adv Res) Vol. 37 Pg. 209-219 (03 2022) ISSN: 2090-1224 [Electronic] Egypt
• PMID: 35475278 (Publication Type: Journal Article)
• Copyright: © 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University.

Chemical References

• Antibodies, Viral
• Epitopes
• Immunoglobulin M
• Proteome

Topics

• Antibodies, Viral
• COVID-19
• Epitopes
• Humans
• Immunity, Humoral
• Immunoglobulin M
• Proteome
• SARS-CoV-2